Drilldown: Medicines

Agomelatine (1) · Amantadine (1) · Amoxapine (1) · Apomorphine (1) · Benztropine (1) · Biperiden (1) · Bromocriptine (1) · Cabergoline (1) · Carbidopa/levodopa (1) · Clomipramine (1) · Clozapine (1) · Desipramine (1) · Duloxetine (1) · Entacapone (1) · Imipramine (1) · Isocarboxazid (1) · Levodopa (1) · Levomilnacipran (1) · Maprotiline (1) · Milnacipran (1) · Moclobemide (1) · Nefazodone (1) · Opicapone (1) · Phenelzine (1) · Protriptyline (1) · Rasagiline (1) · Reboxetine (1) · Rotigotine (1) · Safinamide (1) · Selegiline (1) · Sertraline (1) · Tianeptine (1) · Tolcapone (1) · Tranylcypromine (1) · Trihexyphenidyl (1) · Trimipramine (1)

None (2) · Akineton (1) · Anafranil (1) · Apokyn (1) · Artane (1) · Aurorix (1) · Azilect (1) · Clozaril (Novartis, original brand; 25 mg and 100 mg tablets); FazaClo (orally disintegrating tablets, 12.5/25/100/150/200 mg); Versacloz (oral suspension 50 mg/mL); multiple generics. All clozapine products are subject to the same REMS monitoring requirements. (1) · Cogentin (1) · Comtan (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Dostinex (1) · Edronax (1) · Eldepryl (1) · Fetzima (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Neupro (1) · Norpramin (1) · Ongentys (1) · Parlodel (1) · Parnate (1) · Savella (1) · Serzone (1) · Sinemet (1) · Stablon (1) · Surmontil (1) · Symmetrel (1) · Tasmar (1) · Tofranil (1) · Valdoxan (1) · Vivactil (1) · Xadago (1) · Zoloft (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Central and peripheral COMT inhibitor (1) · D1/D2/D3 receptor agonist (1) · D2 agonist; D1 partial agonist (1) · D2 receptor agonist (1) · Dopamine precursor (1) · Dopamine precursor + DOPA decarboxylase inhibitor (1) · Irreversible non-selective MAO inhibitor (3) · Irreversible selective MAO-B inhibitor (2) · MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Muscarinic receptor antagonist (1) · Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) · NMDA antagonist; dopamine releasing agent (1) · Non-selective dopamine receptor agonist (1) · Once-daily COMT inhibitor (1) · Peripheral COMT inhibitor (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Reversible inhibitor of MAO-A (1) · Selective M1 muscarinic antagonist (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1) · '"`UNIQ--vote-00000049-QINU`"' (1)

None (35) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1)

None (34) · 12.5 mg PO once or twice daily. Titrate gradually: 25-50 mg/day increments every 1-2 days as tolerated. Target dose 300-450 mg/day in divided doses (BID or TID). Most patients stabilize between 200-600 mg/day. Therapeutic plasma level guide: target trough clozapine ≥350 ng/mL. (1) · 25 mg (1)

None (34) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · Clozaril 25 mg and 100 mg tablets; FazaClo orally disintegrating tablets (12.5/25/100/150/200 mg); Versacloz oral suspension 50 mg/mL. All brands subject to identical REMS ANC monitoring requirements. Generic tablets widely available. (1)

None (34) · 200 mg/d (1) · 900 mg/day (split into BID or TID dosing). Clinical practice rarely exceeds 600 mg/day; seizure risk increases substantially above 600 mg/day and requires consideration of prophylactic anticonvulsant.'"`UNIQ--ref-0000004A-QINU`"' (1)

None (33) · Oral (2) · Oral only. No parenteral formulation (a major limitation in acute agitation requiring rapid tranquilization). (1)

None (33) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · Oral peak plasma 2.5 hours. Clinical antipsychotic response typically emerges over weeks with continued titration; full response assessment requires 3-6 months at adequate therapeutic levels. (1)

None (33) · Chronic daily dosing (1) · Due to the half-life of 12 hours (wide range), dosing is BID or TID. Once-daily dosing produces higher peak/trough fluctuations and is generally not used except for a single end-of-day dose in stable patients. (1) · Long (1)

None (34) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (33) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Approximately 50-60% (oral; subject to first-pass metabolism); food does not significantly affect absorption.'"`UNIQ--ref-0000004C-QINU`"' (1) · ~50% (highly variable) (1)

None (34) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1)

None (34) · Rx-only (1) · Rx-only in US (1)